ArticleJournal of clinical laboratory analysis2026
Analysis of Notch1 and Notch3 Signaling Pathway Components in Benign Prostatic Hyperplasia and Prostate Cancer Patients.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer (PCa) and benign prostatic hyperplasia (BPH) significantly affect men's quality of life. Due to low PSA specificity, more sensitive genetic and protein markers are needed. This study comparatively evaluates variations in NOTCH1 and NOTCH3 gene regions-key components of the Notch pathway-and serum protein levels in PCa and BPH patients.
methodsThe study included 90 individuals: 15 healthy controls, 25 BPH, 25 localized PCa (LPCa), and 25 metastatic PCa (MPCa) patients. NOTCH1 and NOTCH3 gene regions were analyzed via Sanger sequencing, and serum protein levels were measured using ELISA.
resultsGenetic analyses revealed that the novel NOTCH1 g.54305 T>A variation (p = 0.0001), rs2133314984 (p = 0.015), and rs577451694 (p = 0.0012) variants were significantly associated with increased PCa risk. Additionally, the NOTCH3 rs746192089 variation was linked to disease risk (p = 0.0005), whereas the rs1044009 variant showed no statistically significant difference. Protein assessments showed that serum NOTCH1 concentrations were significantly lower in LPCa (p = 0.006) and MPCa (p = 0.003) groups than controls. Serum NOTCH3 levels were significantly decreased (p ≤ 0.002) in BPH, LPCa, and MPCa groups, with the lowest levels in the metastatic stage. Wild-type NOTCH1 g.54305 TT and NOTCH3 rs746192089 CC genotypes were associated with significantly higher serum protein expression than mutant-allele genotypes (p = 0.036 and p < 0.001, respectively).
conclusionsIn conclusion, specific NOTCH1 and NOTCH3 variations are linked to disease risk, and decreased serum protein levels correlate with advanced clinical stages, providing insights into the Notch pathway's role in PCa pathogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.